# EDGAR Filing Document

**Accession Number:** 0001829802
**File Stem:** 0001193125-23-066980
**Filing Date:** 2023-3
**Character Count:** 5606
**Document Hash:** 2f55dc74993602e421d5c2aaa7cce02d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-066980.hdr.sgml**: 20230310

**ACCESSION NUMBER**: 0001193125-23-066980

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230310

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230310

**DATE AS OF CHANGE**: 20230310

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sensei Biotherapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001829802
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39980
- **FILM NUMBER:** 23721854

**BUSINESS ADDRESS:**
- **STREET 1:** 620 PROFESSIONAL DRIVE
- **CITY:** GAITHERSBURG
- **STATE:** MD
- **ZIP:** 20879
- **BUSINESS PHONE:** (240) 243-8000

**MAIL ADDRESS:**
- **STREET 1:** 620 PROFESSIONAL DRIVE
- **CITY:** GAITHERSBURG
- **STATE:** MD
- **ZIP:** 20879

?xml version="1.0" encoding="utf-8" ? 8-K

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### Pursuant to Section 13 OR 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): March 10, 2023

------

## Sensei Biotherapeutics, Inc.

#### (Exact name of Registrant as Specified in Its Charter)

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39980** | **83-1863385** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission<br>File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **451 D Street, Suite 710**<br> **Boston, MA** | **02210** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

#### Registrant's Telephone Number, Including Area Code: (240) 243-8000

#### Not Applicable

#### (Former Name or Former Address, if Changed Since Last Report)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☒ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| Common Stock | SNSE | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

#### Item 8.01. Other Events.
Sensei Biotherapeutics, Inc. (the "Company") today confirmed that Apeiron Investment Group Ltd. ("Apeiron") has nominated three candidates to stand for election to the Company's Board of Directors at the Company's 2023 annual meeting of stockholders. The date for the annual meeting has not yet been announced.

The Company's Board of Directors and management team are committed to acting in the best interest of the Company and all stockholders. The Board and management team appreciate the perspectives of all of our stockholders, and welcome constructive input that furthers our goal of creating sustainable long-term value.

Members of the Board and management team have engaged in discussions with representatives of Apeiron. During the course of these discussions and in public communications, Apeiron has suggested proposals for the Board's consideration, including that the Company conduct a tender offer as a means to return capital to stockholders. The Board and management team have considered Apeiron's proposals with its financial and legal advisors and expect to continue to engage with Apeiron on these and other topics.

The Company will review the proposed nominees. The Board will present its formal recommendation with respect to the election of directors and other matters to be considered at the annual meeting in the Company's definitive proxy statement.

Stockholders are not required to take any action at this time.

#### Item 9.01. Financial Statements and Exhibits.
&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits:

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **SENSEI BIOTHERAPEUTICS, INC.** | **SENSEI BIOTHERAPEUTICS, INC.** |
| Date: March 10, 2023 | By: | /s/ Christopher W. Gerry |
|  |  | Christopher W. Gerry<br> General Counsel and Secretary |

---